Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil

dc.creatorAriel Bardach, Ariel
dc.creatorBallivian, Jamile
dc.creatorBagattini, Ângela Maria
dc.creatorRosa, Michelle Quarti Machado da
dc.creatorOliveira , Max Moura de
dc.creatorGomez, Jorge Alberto
dc.creatorCasarini, Agustín
dc.date.accessioned2025-09-26T12:59:46Z
dc.date.available2025-09-26T12:59:46Z
dc.date.issued2025
dc.description.abstractIn Brazil, as the older population has grown at a very rapid pace (by 57.4% over 2010), the number of herpes zoster (HZ) infections is expected to increase. As the Brazilian healthcare system constitutes a complex combination of public-private financing, estimating the true impact of HZ is challenging. The objective was to ascertain the disease burden of HZ and estimate its attributable cost in older adults aged ≥50 y who are users of public and private health services. Disease burden was estimated based on the ZOster ecoNomic Analysis model using Brazil-specific inputs, and any information gap was addressed by the Delphi Panel. The incidence estimates were multiplied by the cost per intervention to calculate the economic burden of the disease. In the absence of HZ vaccination, older adults ≥50 y are projected to experience 359,797 and 23,917 cases of HZ and post-herpetic neuralgia (PHN), with frequent and severe outcomes in the advanced age groups. The estimated mean cost of treatment per patient for HZ and PHN was ~7X and 16X more in the ANS population compared with the SUS. The number of hospitalizations (1339–1424) and median length of stay (4–5 d) were comparable between ANS and SUS. Hospitalization increased the treatment cost >10X (ANS: R$12459.67 –16,343.07; SUS: R$357.93 to 525.08). HZ imposes a substantial economic burden on the healthcare system due to high direct medical (R$357.36 million) and indirect costs (R$440.82 million). These results hold valuable insights for healthcare providers, insurers, and policymakers offering a comprehensive overview of the economic impact of HZ while implementing strategies for prevention of disease.
dc.identifier.citationBARDACH, Ariel  et al. Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil. Human Vaccines & Immunotherapeutics, Austin, v. 21, n. 1, e2520066, 2025. DOI: 10.1080/21645515.2025.2520066. Disponível em: https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2520066. Acesso em: 25 set. 2025.
dc.identifier.doi10.1080/21645515.2025.2520066
dc.identifier.issn2164-5515
dc.identifier.issne- 2164-554X
dc.identifier.urihttps://repositorio.bc.ufg.br//handle/ri/28654
dc.language.isoeng
dc.publisher.countryEstados unidos
dc.publisher.departmentInstituto de Patologia Tropical e Saúde Pública - IPTSP (RMG)
dc.rightsAcesso Aberto
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHerpes zoster
dc.subjectPost herpetic neuralgia
dc.subjectEconomic burden
dc.subjectOlder adults
dc.subjectBrazil
dc.titleModeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
dc.typeArtigo

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
Artigo - Ariel Ariel Bardach - 2025.pdf
Tamanho:
3.41 MB
Formato:
Adobe Portable Document Format

Licença do Pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: